ConductScience.org, home

Paper35323367

Evaluation of Patient-Reported Outcome Differences by Radiotherapy Techniques for Bone Metastases in A Population-Based Healthcare System.

Olson RA and 5 others. Curr Oncol, 2022. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Evaluation of Patient-Reported Outcome Differences by Radiotherapy Techniques for Bone Metastases in A Population-Based Healthcare System. Papers, record 35323367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35323367

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evaluation of Patient-Reported Outcome Differences by Radiotherapy Techniques for Bone Metastases in A Population-Based Healthcare System.
PubMed
Journal
Curr Oncol
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.21
iCite
Revised in PubMed
2024-08-25
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Olson RARobert Ahttps://orcid.org/0000-0003-4532-6197
2LaPointe VVincent
3Benny AAlex
4Chan MMatthewhttps://orcid.org/0000-0003-3510-9068
5Lefresne SShilo
6McKenzie MMichael

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Radiotherapy, ConformalMajor topic
Radiotherapy, Intensity-ModulatedMajor topic
Delivery of Health Care
Humans
Pain
Patient Reported Outcome Measures
Quality of Life

Source PubMed

Download CSV of topics

References19

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130849005Trends in Radiation for Bone Metastasis During a Period of Multiple National Quality Improvement Initiatives.J Oncol Pract2019https://conductscience.org/library/papers/30849005PubMed
222130630Update on the systematic review of palliative radiotherapy trials for bone metastases.Clin Oncol (R Coll Radiol)2012https://conductscience.org/library/papers/22130630PubMed
321277118Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline.Int J Radiat Oncol Biol Phys2011https://conductscience.org/library/papers/21277118PubMed
435106919Patterns of the use of advanced radiation therapy techniques for the management of bone metastases and the associated factors in Victoria.J Med Imaging Radiat Oncol2022https://conductscience.org/library/papers/35106919PubMed
531930016SABR-COMET: a new paradigm of care lights up the twilight of metastatic disease.Ann Transl Med2019https://conductscience.org/library/papers/31930016PubMed
626281828Impact of Using Audit Data to Improve the Evidence-Based Use of Single-Fraction Radiation Therapy for Bone Metastases in British Columbia.Int J Radiat Oncol Biol Phys2016https://conductscience.org/library/papers/26281828PubMed
733309977Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial.Int J Radiat Oncol Biol Phys2021https://conductscience.org/library/papers/33309977PubMed
834068400Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care.Curr Oncol2021https://conductscience.org/library/papers/34068400PubMed
930982687Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.Lancet2019https://conductscience.org/library/papers/30982687PubMed
1032370765Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.BMC Cancer2020https://conductscience.org/library/papers/32370765PubMed
1131426760Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.BMC Cancer2019https://conductscience.org/library/papers/31426760PubMed
1225035213Use of single- versus multiple-fraction palliative radiation therapy for bone metastases: population-based analysis of 16,898 courses in a Canadian province.Int J Radiat Oncol Biol Phys2014https://conductscience.org/library/papers/25035213PubMed
1334126044Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial.Lancet Oncol2021https://conductscience.org/library/papers/34126044PubMed
1432584700Advanced Radiation Therapy Technology Use in the Treatment of Bone Metastases in a Public, Salary-Funded, Non-Incentivized Health Care System.JCO Oncol Pract2021https://conductscience.org/library/papers/32584700PubMed
1529264976Provincial development of a patient-reported outcome initiative to guide patient care, quality improvement, and research.Healthc Manage Forum2018https://conductscience.org/library/papers/29264976PubMed
1635017007Quality of Life After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases.Int J Radiat Oncol Biol Phys2022https://conductscience.org/library/papers/35017007PubMed
1727072939Comparison of patient-reported outcomes with single versus multiple fraction palliative radiotherapy for bone metastasis in a population-based cohort.Radiother Oncol2016https://conductscience.org/library/papers/27072939PubMed
1831660894SUPR-3D: A randomized phase iii trial comparing simple unplanned palliative radiotherapy versus 3d conformal radiotherapy for patients with bone metastases: study protocol.BMC Cancer2019https://conductscience.org/library/papers/31660894PubMed
1932484754Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.J Clin Oncol2020https://conductscience.org/library/papers/32484754PubMed

Download CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42032485SPINAL: study protocol for a multicenter non-inferiority trial evaluating reduce vertebral irradiation volumes in palliative radiotherapy for spinal bone metastases on analgesic efficacy.BMC Cancer2026https://conductscience.org/library/papers/42032485PubMed
35621686Striving to Fill in Gaps between Clinical Practice and Standards: The Evolution of a Pan-Canadian Approach to Patient-Reported Outcomes Use.Curr Oncol2022https://conductscience.org/library/papers/35621686PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35323367

GET https://conductscience.org/api/papers/v1/35323367/authors